Cargando…
Patient-reported experiences and views on the Cytosponge test: a mixed-methods analysis from the BEST3 trial
OBJECTIVES: The BEST3 trial demonstrated the efficacy and safety of the Cytosponge-trefoil factor 3, a cell collection device coupled with the biomarker trefoil factor 3, as a tool for detecting Barrett’s oesophagus, a precursor of oesophageal adenocarcinoma (OAC), in primary care. In this nested st...
Autores principales: | Maroni, Roberta, Barnes, Jessica, Offman, Judith, Scheibl, Fiona, Smith, Samuel G, Debiram-Beecham, Irene, Waller, Jo, Sasieni, Peter, Fitzgerald, Rebecca C, Rubin, Greg, Walter, Fiona M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8990713/ https://www.ncbi.nlm.nih.gov/pubmed/35393308 http://dx.doi.org/10.1136/bmjopen-2021-054258 |
Ejemplares similares
-
Predictors of the experience of a Cytosponge test: analysis of patient survey data from the BEST3 trial
por: Ghimire, Bhagabati, et al.
Publicado: (2023) -
Cytosponge-trefoil factor 3 versus usual care to identify Barrett's oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial
por: Fitzgerald, Rebecca C, et al.
Publicado: (2020) -
Barrett’s oESophagus trial 3 (BEST3): study protocol for a randomised controlled trial comparing the Cytosponge-TFF3 test with usual care to facilitate the diagnosis of oesophageal pre-cancer in primary care patients with chronic acid reflux
por: Offman, Judith, et al.
Publicado: (2018) -
Acceptability of the Cytosponge procedure for detecting Barrett's oesophagus: a qualitative study
por: Freeman, Madeleine, et al.
Publicado: (2017) -
Use of Cytosponge as a triaging tool to upper gastrointestinal endoscopy during the COVID-19 pandemic
por: di Pietro, Massimiliano, et al.
Publicado: (2020)